Peregrine shares spike on Ph2 cancer data

Shares of Peregrine Pharmaceuticals ($PPHM) spiked 20% this morning after the company reported that advanced and metastatic breast cancer patients taking a combination of bavituximab and docetaxel experienced a median survival rate of 20.7 months in a prior single arm Phase II study involving 46 patients. Release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.